DSpace コレクション: 2010-04
http://hdl.handle.net/2433/109909
2010-042024-03-29T12:34:19Z4cm以下の小径腎腫瘍に対する術式とCKDの検討
http://hdl.handle.net/2433/109924
タイトル: 4cm以下の小径腎腫瘍に対する術式とCKDの検討
著者: 杉本, 公一; 橋本, 潔; 江左, 篤宣
抄録: We retrospectively studied 63 patients undergoing partial or radical nephrectomy for solitary, renal cortical tumor (≦4 cm) between 1997 and 2008. Analysis was undertaken, with chronic kidney disease defined as glomerular filtration rate (GFR) lower than 60 ml/min per 1.73 m2 . Multivariable analysis showed that radical nephrectomy remained an independent risk factor for patients developing new onset of GFR lower than 60 ml/min per 1.73 m2 (hazard ratio 3.158 [95% CI 1.335-7.473]). Radical nephrectomy is a significant risk factor for the development of chronic kidney disease.2010-04-01T00:00:00Zホルモン抵抗性前立腺癌に対する低用量Docetaxel, Estramustine, Dexamethasone 併用療法の検討
http://hdl.handle.net/2433/109923
タイトル: ホルモン抵抗性前立腺癌に対する低用量Docetaxel, Estramustine, Dexamethasone 併用療法の検討
著者: 小林, 一樹; 横西, 哲広; 伊藤, 悠亮; 松本, 達也; 梅本, 晋; 逢坂, 公人; 中村, 昌史; 小貫, 竜昭; 小宮, 敦; 大古, 美治; 酒井, 直樹; 野口, 純男; 岸, 洋一; 横溝, 由美子; 河合, 正記; 岡島, 和登; 田尻, 雄大; 藤川, 敦; 太田, 純一; 湯村, 寧; 森山, 正敏
抄録: The objective of this study was to evaluate the efficacy and safety of low-dose docetaxel, estramustine and dexamethasone combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC). Sixty-nine patients with HRPC were enrolled. Docetaxel was given at a dose of 25 mg/m2 on days 1 and 8 every 3 weeks, oral estramustine 280 mg twice daily on days 1 to 3 and 8 to 10, and oral dexamethasone 1mg daily throughout the course. Cycles were repeated every 21 days. Treatment was continued until disease progression or excessive toxicity. Patients were evaluated for response and toxicity. Patients received a median of eleven cycles (range : 1-25). Prostatic-specific antigen (PSA) was decreased greater than 50% in 53 (77%) out of 69 patients and median duration of PSA response was 10.2 months. Median time to progression and overall survival 10.2 and 24 months, respectively. Grade 1-2 fatigue was the most common toxicity observed in 10 (15%) patients. Grade 3-4 toxicities were observed in five (7%) patients (2 thrombosis, 2 bilirubin elevation, and 1 aspartate transaminase/alanine transaminase elevation). Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy is an effective and well tolerated treatment for Japanese HRPC patients.2010-04-01T00:00:00Z前立腺肥大症患者の夜間頻尿と睡眠障害に対するナフトピジルの有用性について
http://hdl.handle.net/2433/109922
タイトル: 前立腺肥大症患者の夜間頻尿と睡眠障害に対するナフトピジルの有用性について
著者: 岩城, 秀出洙; 成田, 充弘; 曽我, 弘樹; 坂野, 祐司; 小西, 平; 岡田, 裕作
抄録: Nocturnal urinary frequency is a predominant complaint among males presenting with benign prostatic hyperplasia (BPH), which markedly impacts quality of life (QOL) and often causes sleep disturbance. We studied the efficacy of naftopidil an alpha 1-adrenoreceptor antagonist used for treatment of BPH for improvement of nocturia and consequent sleep disturbance. Twenty-five patients diagnosed with BPH were administered daily oral doses of naftopidil (50 or 75 mg/day) for eight weeks. The symptoms were assessed quantitatively using the following criteria : International Prostate Symptoms Score (I-PSS), QOL index, frequency volume chart, and Pittsburgh Sleep Quality Index (PSQI). After treatment, the mean±SD of total I-PSS and nocturia decreased from 16.9±5.2 to 10.3±4.9 (p<0.001) and 3.5±1.2 to 2.3±1.3 (p< 0.001), respectively. In addition, all categories of storage symptoms in I-PSS were also significantly improved. PSQI results were obtained in 21 of the 25 patients, and decreased from 6.4±4.2 to 5.3±3.5 (p=0.026) (normal range : less than 5.5). This is the first report of a quantitative analysis of the effect of naftopidil on sleep quality in BPH patients. In conclusion, naftopidil appears to be an effective agent not only for nocturia and other urinary storage symptoms, but also for improving the quality of sleep.2010-04-01T00:00:00Z下部尿路症状(LUTS) を有し,慢性骨盤痛症候群(CPPS) 症状を合併する患者に対するα1 アドレナリン受容体遮断薬ナフトピジルによる臨床的有効性の検討 : 日本語版NIH-CPSI を用いた投与前後4週間の比較
http://hdl.handle.net/2433/109921
タイトル: 下部尿路症状(LUTS) を有し,慢性骨盤痛症候群(CPPS) 症状を合併する患者に対するα1 アドレナリン受容体遮断薬ナフトピジルによる臨床的有効性の検討 : 日本語版NIH-CPSI を用いた投与前後4週間の比較
著者: 鈴木, 明; 大日向, 充; 藤島, 幹彦; 平野, 繁; 工藤, 卓次; 船木, 廣英; 赤坂, 俊幸
抄録: We investigated the effect of naftopidil an α1 adrenoceptor antagonist on non-bacterial chronic pelvic pain syndrome (CPPS) in middle-aged and older male patients with lower urinary tract symptoms (LUTS). Patients who had given informed consent were treated with naftopidil (daily 50 mg), and were evaluated using the Japanese edition of NIH chronic prostatitis symptom index (NIH-CPSI) and the international prostate symptom score (IPSS) at 2 and 4 weeks after the administration. The NIH-CPSI (total score) was significantly improved by naftopidil for 4 weeks (11.5±6.0, n=62, p<0.001) as compared with the baseline (19.8±5.7). Other items of NIH-CPSI of pain, urinary symptoms, and quality of life-impact, and IPSS were also ameliorated by naftopidil as compared with the baseline (n=62, p<0.001 each). One patient had slight dizziness, but no severe adverse events were noted in any patient. It is suggested that naftopidil could be an effective and safe therapeutic option for middle-aged and older male LUTS patients with CPPS.2010-04-01T00:00:00Z